Molecular Partners AG (NASDAQ:MOLN – Get Free Report)’s stock price shot up 7.1% during trading on Monday . The company traded as high as $5.44 and last traded at $5.44. 2,138 shares changed hands during trading, a decline of 90% from the average session volume of 22,256 shares. The stock had previously closed at $5.08.
Analysts Set New Price Targets
Separately, Leerink Partnrs upgraded shares of Molecular Partners to a “strong-buy” rating in a research note on Monday, October 7th.
View Our Latest Stock Report on MOLN
Molecular Partners Stock Up 7.1 %
About Molecular Partners
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Recommended Stories
- Five stocks we like better than Molecular Partners
- What Are Trending Stocks? Trending Stocks Explained
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- What is the Euro STOXX 50 Index?
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.